Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s traded shares stood at 12.62 million during the last session, with the company’s beta value hitting 0.40. At the close of trading, the stock’s price was $0.45, to imply an increase of 9.76% or $0.04 in intraday trading. The CYCC share’s 52-week high remains $8.65, putting it -1822.22% down since that peak but still an impressive 15.56% since price per share fell to its 52-week low of $0.38. The company has a valuation of $0.97M, with an average of 2.48 million shares in intraday trading volume over the past 10 days and average of 1.19 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cyclacel Pharmaceuticals Inc (CYCC), translating to a mean rating of 3.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CYCC a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
After registering a 9.76% upside in the last session, Cyclacel Pharmaceuticals Inc (CYCC) has traded red over the past five days. The 5-day price performance for the stock is 8.41%, and -44.68% over 30 days. With these gigs, the year-to-date price performance is -83.15%. Short interest in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) saw shorts transact 66765.0 shares and set a 0.03 days time to cover.
The extremes give us $1 and $1 for target low and target high price respectively. As such, CYCC has been trading -122.22% off suggested target high and -122.22% from its likely low.
Cyclacel Pharmaceuticals Inc (CYCC) estimates and forecasts
Looking at statistics comparing Cyclacel Pharmaceuticals Inc share performance against respective industry, we note that the company has outperformed competitors. Cyclacel Pharmaceuticals Inc (CYCC) shares are -81.56% down over the last 6 months, with its year-to-date growth rate higher than industry average at 91.44% against 17.10%.
CYCC Dividends
Cyclacel Pharmaceuticals Inc has its next earnings report out in December. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
Cyclacel Pharmaceuticals Inc insiders hold 4.82% of total outstanding shares, with institutional holders owning 18.03% of the shares at 18.94% float percentage. In total, 18.03% institutions holds shares in the company.
